Patisiran for advanced heart failure with hereditary transthyretin cardiac amyloidosis

Makiko Nakamura, Teruhiko Imamura*, Koichiro Kinugawa

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

We experienced a 78-year-old woman who was diagnosed with hereditary transthyretin cardiac amyloidosis and administered patisiran for advanced heart failure refractory to tafamidis. The levels of N-terminal pro B-type natriuretic peptide and left ventricular mass index decreased following the six-month patisiran treatment without any complications. Patisiran might be a promising disease-modifying drug for hereditary transthyretin cardiac amyloidosis even in its advanced stage, although further evaluation in a large cohort is warranted.

Original languageEnglish
Pages (from-to)177-180
Number of pages4
JournalJournal of Cardiology Cases
Volume23
Issue number4
DOIs
StatePublished - 2021/04

Keywords

  • Heart failure with preserved ejection fraction
  • Transthyretin cardiac amyloidosis
  • siRNA

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Patisiran for advanced heart failure with hereditary transthyretin cardiac amyloidosis'. Together they form a unique fingerprint.

Cite this